Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - cefotaxime sodium - powder for solution for injection - 2gram

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - cefotaxime sodium - powder for solution for injection - 1gram

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - cefotaxime sodium - powder for solution for injection - 500mg

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefotaxime sodium, quantity: 2096.4 mg (equivalent: cefotaxime, qty 2000 mg) - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower); infections of the urinary tract; septicaemia (concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism); intra-abdominal infection; gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoea); ear, nose and throat infections; skin and skin structure infections; bone and joint infections; meningitis: cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or benzylpenicillin) for initial therapy in children (excluding neonates) pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infec

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cefotaxime sodium 1.048 g equivalent to 1 g cefotaxime;  ;   - powder for injection - 1 g - active: cefotaxime sodium 1.048 g equivalent to 1 g cefotaxime     - dbl™ cefotaxime sodium for injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemia. respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft tissue infections: cellulitis, peritonitis and wound infections. bone and joint infections: osteomyelitis, septic arthritis. obstetric and gynaecological infections: pelvic inflammatory disease. gonorrhoea: particularly if penicillin-resistant. other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of dbl™ cefotaxime sodium for injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. dbl™ cefotaxime sodium for injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cefotaxime sodium 2.096 g equivalent to 2 g cefotaxime;  ;   - powder for injection - 2 g - active: cefotaxime sodium 2.096 g equivalent to 2 g cefotaxime     - dbl™ cefotaxime sodium for injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemia. respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft tissue infections: cellulitis, peritonitis and wound infections. bone and joint infections: osteomyelitis, septic arthritis. obstetric and gynaecological infections: pelvic inflammatory disease. gonorrhoea: particularly if penicillin-resistant. other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of dbl™ cefotaxime sodium for injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. dbl™ cefotaxime sodium for injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cefotaxime sodium 525mg equivalent to 500 mg cefotaxime;  ;   - powder for injection - 500 mg - active: cefotaxime sodium 525mg equivalent to 500 mg cefotaxime     - dbl™ cefotaxime sodium for injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemia. respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft tissue infections: cellulitis, peritonitis and wound infections. bone and joint infections: osteomyelitis, septic arthritis. obstetric and gynaecological infections: pelvic inflammatory disease. gonorrhoea: particularly if penicillin-resistant. other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of dbl™ cefotaxime sodium for injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. dbl™ cefotaxime sodium for injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

Malte - anglais - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - cefotaxime - powder for solution for infusion or injection - cefotaxime 1 g - antibacterials for systemic use

Malte - anglais - Medicines Authority

wockhardt uk limited - cefotaxime sodium - powder for solution for infusion or injection - cefotaxime sodium 2 g - antibacterials for systemic use

Malte - anglais - Medicines Authority

villerton invest s.a. - cefotaxime sodium - powder for solution for infusion or injection - cefotaxime sodium 500 mg - antibacterials for systemic use